Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application

Leukemia. 2013 Dec;27(12):2397-403. doi: 10.1038/leu.2013.150. Epub 2013 May 14.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy*
  • Humans
  • Multiple Myeloma / enzymology
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / pathology*
  • Phosphoinositide-3 Kinase Inhibitors*
  • Proteasome Endopeptidase Complex / metabolism*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*

Substances

  • Phosphoinositide-3 Kinase Inhibitors
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Proteasome Endopeptidase Complex